Plain English Summary
Background and study aims
The aim of this study is to assess the safety and activity of cisplatin, methotrexate and vinblastine (CMV) chemotherapy in patients with pure squamous cell carcinoma (SCC) of the urinary tract. SCC of the urinary tract is rare in the UK and has a poor prognosis compared with the more common type of transitional cell carcinoma (TCC). In TCC cisplatin chemotherapy has been shown to be effective and so this trial was developed to investigate the activity of cisplatin based chemotherapy in the SCC setting.
Who can participate?
Patients (any age, gender) with SCC of the urinary tract.
What does the study involve?
CMV is given as three 21-day cycles of intravenous infusions (into a vein) of methotrexate (day 1 & 8), vinblastine (day 1 & 8) and cisplatin (day 2). Folinic acid is also given 24 h after each methotrexate injection, either orally or intravenously, every 6 h for 24 h (4 times).
What are the possible benefits and risks of participating?
This study aims to find that CMV is active with few side effects in SCC, and this will then justify it being be tested in a larger group. The options for these patients can be limited. Giving a combination of 3 chemotherapies could increase side effects and the time receiving an intravenous infusion.
Where is the study run from?
Hospitals in the UK, Norway and Poland.
When is the study starting and how long is it expected to run for?
It recruited from October 1993 to February 1999
Who is funding the study?
Medical Research Council (UK)
Who is the main contact?
Gareth Griffiths
Trial website
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
BA08 August 1993
Study information
Scientific title
MRC BA08 trial: A phase II trial of cisplatin, methotrexate and vinblastine (CMV) chemotherapy for pure squamous cell cancer of the urinary tract
Acronym
BA08
Study hypothesis
Cisplatin, methotrexate and vinblastine (CMV) chemotherapy is effective in patients with squamous cell carcinoma of the bladder
Ethics approval
This trial was conducted in the 1990s where each participating centre approved through a Regional Ethics Committee (REC) prior to patient recruitment.
Study design
Phase II single-arm non-randomised open-label multicentre trial
Primary study design
Interventional
Secondary study design
Non randomised study
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use contact details to request a participant information sheet.
Condition
Squamous cell carcinoma of the bladder
Intervention
At UK secondary care NHS Trusts all patients received three 21-day cycles of CMV chemotherapy (cisplatin 100 mg/m2 given on day 2, methotrexate at 30 mg/m2 and vinblastine at 4 mg/m2, both given intravenously, on days 1 and 8) from their treating clinician. Folinic acid was given 24 h after each methotrexate injection at a dose of 15 mg orally or intravenously every 6 h for four doses. Cisplatin was given following a period of intravenous hydration in which at least 1 l of normal saline was given and was not administered until urine output was measured as equal to or exceeding 100 ml/h for 4 h. The administration of cisplatin was followed by 2 l further hydration with normal saline, with supplementary potassium chloride and magnesium sulphate.
Intervention type
Drug
Phase
Phase II
Drug names
cisplatin, methotrexate, vinblastine
Primary outcome measure
The primary endpoint of the study was overall response at 9 weeks (or post-chemotherapy if chemotherapy was stopped) after the commencement of the treatment (i.e. end of 3 cycles).
Definition of response was assessed by the treating clinician as follows:
Complete response (CR): The disappearance of all known malignant disease. If the initial primary tumour was in the bladder, and cystectomy has not been performed, an assessment should be made of this primary tumour.
If the response of the primary bladder tumour is classified as complete response (CR) on bimanual examination and cystoscopy, a deep resection biopsy should be performed at the site of the original tumour and recorded as biopsy positive or negative, i.e:
CR(B-) Complete response on cystoscopic and bimanual examination. Biopsy negative.
CR(B+) Complete response on cystoscopic and bimanual examination. Biopsy positive.
CR(Bo) Complete response on cystoscopic and bimanual examination. Biopsy not done.
Partial response (PR) : At least 50% reduction of the sum of the products of the two largest perpendicular diameters of all lesions measured at registration. In addition there can be no appearance of new lesions nor progression of any lesion.
No change (NC): Less than 50% reduction of the sum of the products of the two largest perpendicular diameters of all lesions measured at registration and no lesion measured at registration has shown a 25% increase in size.
Progressive disease: A 25% or more increase in the size of one or more lesions measured at registration, or the appearance of new lesions.
Secondary outcome measures
1. Treatment compliance
2. Safety
3. All-cause mortality
4. Time to all-cause death
These were recorded by NHS staff at the treating hospitals on Case Report Forms (CRF) at the time points of the completion of chemotherapy, first follow-up at 6 months, subsequent 6-monthly follow-ups or death. Overall survival was calculated as the time from the date of registration to date of death or censored at the time last seen if still alive.
Overall trial start date
01/01/1993
Overall trial end date
01/05/2001
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
1. Pure squamous cell carcinoma of the urinary tract in one of the following groups:
1.1. initial presentation with T3-T4 disease
1.2. pelvic relapse after radiotherapy or surgery
1.3. nodal or metastatic disease
2. At least one site of disease assessable for response by clinical examination or imaging. One or more of the sites below can be used to assess response:
2.1. primary bladder tumour (satisfactory measurements of the primary tumour if present and measureable, must have been made by bimanual examination after transurethral resection (TUR))
2.2. other primary tumours in the urinary tract (satisfactory measurements of the primary tumour in the urinary tract, if present and measureable, must have been made by clinical examination or appropriate imaging)
2.3. pelvic relapse after radiotherapy or surgery (at least one indicator lesion must be measurable by clinical examination or appropriate imaging)
2.4. nodal or metastatic disease (at least one indicator lesion must be measurable by clinical examination or appropriate imaging. NB: Bone metastases cannot be used as an indicator lesion.
3. Calculated glomerular filtration rate (GFR), calculated by the method of Cockcroft and Gault (1976) >50 ml/min. In patients with impaired renal function secondary to ureteric obstruction this may be relieved by ureteric stents or nephrostomies, and if the renal function then recovers the patient will be eligible.
4. White blood cell count >3.5 x 10(9)/l and platelet count >100 x 10(9)/l
5. No previous systemic treatment with chemotherapy
6. No concomitant or previous malignancy other than basal cell carcinoma of skin or carcinoma in-situ of the cervix
7. Fit to tolerate CMV
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
Maximum of 45
Participant exclusion criteria
1. Transitional cell carcinoma with squamous metaplasia, or other mixed tumours
2. Co-existing illness (e.g. cardiac failure) that may compromise administration of CMV chemotherapy
Recruitment start date
01/10/1993
Recruitment end date
28/02/1999
Locations
Countries of recruitment
Norway, Poland, United Kingdom
Trial participating centre
Beatson Oncology Centre
G12 0YN
United Kingdom
Trial participating centre
Christie Hospital
M20 4BX
United Kingdom
Trial participating centre
Clatterbridge Hospital
L9 7AL
United Kingdom
Trial participating centre
Middlesex Hospital
TW7 6AF
United Kingdom
Trial participating centre
Western General
EH4 2XU
United Kingdom
Trial participating centre
Guys Hospital
SE1 9RT
United Kingdom
Trial participating centre
Newcastle General Hospital
NE4 6BE
United Kingdom
Trial participating centre
Queen Elizabeth Hospital
B15 2WB
United Kingdom
Trial participating centre
Norwegian Radium Hospital
0316 Oslo
Norway
Trial participating centre
North Staffordshire Hospital
ST4 7LN
United Kingdom
Trial participating centre
Warsaw Oncology Centre
00-001 Warszawa
Poland
Sponsor information
Organisation
Medical Research Council
Sponsor details
MRC Clinical Trials Unit at UCL
Institute of Clinical Trials and Methodology
90 High Holborn
2nd Floor
London
London
WC1V 6LJ
United Kingdom
+44 (0) 20 7670 4700
enquiries@ctu.mrc.ac.uk
Sponsor type
Government
Website
Funders
Funder type
Not defined
Funder name
Medical Research Council
Alternative name(s)
MRC
Funding Body Type
government organisation
Funding Body Subtype
Federal/National Government
Location
United Kingdom
Results and Publications
Publication and dissemination plan
Planned publication in a high-impact peer reviewed journal.
PLD sharing statement
The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication.
Intention to publish date
01/06/2019
Participant level data
Available on request
Basic results (scientific)
Publication list
2019 results in https://www.ncbi.nlm.nih.gov/pubmed/30650143 (added 22/01/2019)